Crispr Therapeutics AG Receives Buy Rating and $99 Price Target from Evercore ISI Analyst Liisa Bayko.

Crispr Therapeutics AG received a Buy rating and $99.00 price target from Evercore ISI analyst Liisa Bayko. The company's shares closed at $54.13. Bayko has a success rate of 45.95% on recommended stocks. Additionally, Truist Financial's Joon Lee also gave the company a Buy rating, while Bernstein maintained a Hold rating. CRSP's market cap is $4.92B and P/E ratio is -9.98.

Crispr Therapeutics AG (CRSP), a leading gene-editing company, has received a significant boost from analysts at Evercore ISI. The firm's analyst, Liisa Bayko, has given the company a Buy rating and set a price target of $99.00. This marks a notable increase from the previous target of $80, reflecting the strong performance of CRSP's shares, which closed at $54.13 on July 2, 2025 [1].

Bayko, who covers the Healthcare sector, has a success rate of 45.95% on recommended stocks, according to TipRanks.com. Her positive outlook on CRSP is supported by the company's impressive second-quarter results, which saw a 114% quarter-over-quarter increase in CASGEVY sales to $30 million. The significant growth came from the treatment being infused in 16 patients, double the eight infusions done in the first quarter [1].

In addition to Evercore ISI's bullish rating, Truist Financial's Joon Lee also gave CRSP a Buy rating. Meanwhile, Bernstein maintained a Hold rating. The company's market cap stands at $4.92 billion, and its P/E ratio is -9.98, reflecting its strong market position [2].

CRSP's focus on developing transformative, gene-based medicines for serious diseases, using its proprietary CRISPR/Cas9 platform, has positioned it as a leader in the gene-editing space. The company's pipeline includes treatments for hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

While the current market sentiment is generally positive, investors should remain cautious and conduct thorough research before making investment decisions. CRSP's reliance on large project cycles and the inherent risks associated with gene-editing technology should be carefully considered.

References:
[1] https://finance.yahoo.com/news/h-c-wainwright-lifts-crispr-042128397.html
[2] https://www.theglobeandmail.com/investing/markets/stocks/TLRY/pressreleases/34386565/analysts-are-bullish-on-these-healthcare-stocks-editas-medicine-edit-tilray-tlry/